Impact of prior immunotherapy on paclitaxel/bevacizumab in advanced non-squamous non-small cell lung cancer.

ABSTRACT: Immunotherapy is becoming essential in the management of advanced non-small cell lung cancer (NSCLC); however, the best treatment sequence remains to be determined. Some data suggest that immunotherapy prior to chemotherapy with paclitaxel/bevacizumab (PB) appears to be an interesting option. Here, we study this sequence in a validation cohort from the Bordeaux Cancer Institute (France). We retrospectively included all patients with NSCLC diagnosed between 2015 and 2021, treated with PB directly after immunotherapy (CAI) or without prior exposure to immunotherapy (CWPI). The primary outcome was the time to treatment discontinuation (TTD), and the secondary endpoints were progression-free survival (PFS), overall survival (OS), overall response rate (ORR), and disease control rate (DCR). We

SUBMITTER: Peyret A 

PROVIDER: S-EPMC12597745 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature